GlobalResearch and clinical trials
Soticlestat did not reduce drop seizures in Lennox-Gastaut syndrome in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The phase 3 trial included 270 people aged 2 to 55 years, and half received the drug and half received placebo. The trial lasted 16 weeks. There was no difference between the two groups in seizures causing falls. The most common side effect was sleepiness.
What does it mean for patients and families?
This negative result is also valuable. The researchers stated that this approach is not suitable for LGS. Talk to your doctor before making any change to your current treatment.
Source
Scientific paper: A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome. Epilepsia, 2026. DOI: 10.1002/epi.70216 · PubMed 41891667
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Lennox-Gastaut syndrome (LGS)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.